{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:16:03Z","timestamp":1759497363091},"reference-count":42,"publisher":"Impact Journals, LLC","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,2,23]]},"DOI":"10.18632\/oncotarget.24222","type":"journal-article","created":{"date-parts":[[2018,1,13]],"date-time":"2018-01-13T11:12:59Z","timestamp":1515841979000},"page":"12389-12399","source":"Crossref","is-referenced-by-count":2,"title":["Thiazolidinediones versus metformin on improving abnormal liver enzymes in patients with type 2 diabetes mellitus: a meta-analysis"],"prefix":"10.18632","volume":"9","author":[{"given":"Chunmei","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyue","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shandong Provincial Qianfoshan Hospital, Shandong University of Traditional Chinese Medicine, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwei","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Qilu Hospital of Shandong University, Shandong University, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Qilu Hospital of Shandong University, Shandong University, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2018,1,13]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Matthews","year":"2012","journal-title":"Diabetes Care"},{"key":"2","doi-asserted-by":"publisher","first-page":"e82880","DOI":"10.1371\/journal.pone.0082880","article-title":"Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"9","author":"Kleefstra","year":"2014","journal-title":"PLoS One"},{"key":"3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/qjmed\/hcl116","article-title":"Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes mellitus","volume":"99","author":"Aithal","year":"2006","journal-title":"QJM"},{"key":"4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s40064-015-1135-z","article-title":"Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury","volume":"4","author":"Ogawa","year":"2015","journal-title":"Springerplus"},{"key":"5","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jhep.2015.02.041","article-title":"Current efforts and trends in the treatment of NASH","volume":"62","author":"Sanyal","year":"2015","journal-title":"J Hepatol"},{"key":"6","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1002\/hep.28392","article-title":"Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice","volume":"63","author":"Dalle Grave","year":"2016","journal-title":"Hepatology"},{"key":"7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Romero-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"8","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.2174\/13816128113196660676","article-title":"The role of oral antidiabetic agents and incretin mimetics in type 2 diabetic patients with non-alcoholic fatty liver disease","volume":"20","author":"Maltezos","year":"2014","journal-title":"Curr Pharm Des"},{"key":"9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.diabres.2015.07.002","article-title":"Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents","volume":"110","author":"Colagiuri","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"Laird","year":"1986","journal-title":"Control Clin Trials"},{"key":"11","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Mazumdar","year":"1994","journal-title":"Biometrics"},{"key":"12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2337\/diacare.27.1.141","article-title":"One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes","volume":"27","author":"Charbonnel","year":"2004","journal-title":"Diabetes Care"},{"key":"13","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/j.1464-5491.2005.01595.x","article-title":"Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide","volume":"22","author":"Schernthaner","year":"2005","journal-title":"Diabet Med"},{"key":"14","unstructured":"Iliadis, Kadoglou, Hatzitolios, Karamouzis, Alevizos, Karamitsos. Metabolic effects of rosiglitazone and metformin in Greek patients with recently diagnosed type 2 diabetes.In Vivo. 2007; 21:1107\u201314."},{"key":"15","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1055\/s-0029-1202792","article-title":"Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome","volume":"117","author":"Itoh","year":"2009","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00592-011-0276-y","article-title":"The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus","volume":"48","author":"Erem","year":"2011","journal-title":"Acta Diabetol"},{"key":"17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.diabres.2005.02.011","article-title":"Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes","volume":"70","author":"Matthews","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"key":"18","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/clpt.2014.167","article-title":"Application of systems pharmacology to explore mechanisms of hepatotoxicity","volume":"96","author":"Abernethy","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.taap.2015.02.018","article-title":"Characterizing the mechanism of thiazolidinedione-induced hepatotoxicity: Anmodel in mitochondria","volume":"284","author":"Ding","year":"2015","journal-title":"Toxicol Appl Pharmacol"},{"key":"20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/dmrr.2561","article-title":"Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes","volume":"30","author":"Zou","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"key":"21","doi-asserted-by":"publisher","first-page":"846","DOI":"10.4254\/wjh.v7.i6.846","article-title":"Non-alcoholic fatty liver disease: the diagnosis and management","volume":"7","author":"El-Den Ashmawy","year":"2015","journal-title":"World J Hepatol"},{"key":"22","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00204-016-1737-4","article-title":"The current role of thiazolidinediones in diabetes management","volume":"90","author":"Elisaf","year":"2016","journal-title":"Arch Toxicol"},{"key":"23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cmet.2015.01.003","article-title":"Metformin action: concentrations matter","volume":"21","author":"Wondisford","year":"2015","journal-title":"Cell Metab"},{"key":"24","doi-asserted-by":"publisher","first-page":"816856","DOI":"10.1155\/2015\/816856","article-title":"Review of the structural and dynamic mechanisms of PPAR\u03b3 partial agonism","volume":"2015","author":"Bruning","year":"2015","journal-title":"PPAR Res"},{"key":"25","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1517\/17425255.2014.902444","article-title":"Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease","volume":"10","author":"Scheen","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"26","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.jhep.2011.03.016","article-title":"The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis","volume":"55","author":"George","year":"2011","journal-title":"J Hepatol"},{"key":"27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/MEG.0b013e32832e2baf","article-title":"Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease","volume":"22","author":"Akarca","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2036.2008.03723.x","article-title":"Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis","volume":"28","author":"Ozden","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"29","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1002\/hep.22109","article-title":"Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease","volume":"47","author":"Bodenheimer","year":"2008","journal-title":"Hepatology"},{"key":"30","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.3390\/ijms17091545","article-title":"Correlations of hepatic hemodynamics, liver function, and fibrosis markers in nonalcoholic fatty liver disease: comparison with chronic hepatitis related to hepatitis C virus","volume":"17","author":"Noguchi","year":"2016","journal-title":"Int J Mol Sci"},{"key":"31","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/hep.21661","article-title":"The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis","volume":"46","author":"Hoofnagle","year":"2007","journal-title":"Hepatology"},{"key":"32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2337\/diaclin.23.3.115","article-title":"Elevated Liver Function Tests in Type 2 Diabetes","volume":"23","author":"Harris","year":"2005","journal-title":"Clin Diabetes"},{"key":"33","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1002\/hep.26226","article-title":"Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease","volume":"58","author":"Fromenty","year":"2013","journal-title":"Hepatology"},{"key":"34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1172\/JCI200422422","article-title":"Molecular mediators of hepatic steatosis and liver injury","volume":"114","author":"Horton","year":"2004","journal-title":"J Clin Invest"},{"key":"35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.4254\/wjh.v7.i1.44","article-title":"Adiponectin serum level in chronic hepatitis C infection and therapeutic profile","volume":"7","author":"Abenavoli","year":"2015","journal-title":"World J Hepatol"},{"key":"36","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.metabol.2006.06.016","article-title":"Tumor necrosis factor-\u03b1-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line","volume":"55","author":"Kaneko","year":"2006","journal-title":"Metabolism"},{"key":"37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1034\/j.1600-0676.2000.020003191.x","article-title":"The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease","volume":"20","author":"Crabb","year":"2000","journal-title":"Liver"},{"key":"38","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1002\/hep.27715","article-title":"Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation","volume":"61","author":"Poupon","year":"2015","journal-title":"Hepatology"},{"key":"39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/bcpt.12104","article-title":"Effect of rosiglitazone on liver structure and function in genetically diabetic Akita mice","volume":"113","author":"Lijnen","year":"2013","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"40","article-title":"Comparison of hepatocellular carcinoma risk between patients treated with glimepiride and gliclazide","author":"Kang","year":"2017","journal-title":"Diabetes Metab"},{"key":"41","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/79697","article-title":"Metformin reverses fatty liver disease in obese, leptin-deficient mice","volume":"6","author":"Diehl","year":"2000","journal-title":"Nat Med"},{"key":"42","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1517\/14740338.5.6.827","article-title":"Comparative safety of newer oral antidiabetic drugs","volume":"5","author":"Krentz","year":"2006","journal-title":"Expert Opin Drug Saf"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24222","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T13:35:39Z","timestamp":1719754539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,13]]},"references-count":42,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2018,2,23]]}},"alternative-id":["24222","29552319"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.24222","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,13]]}}}